Cencora, Inc. $COR Shares Sold by Avanza Fonder AB

Avanza Fonder AB trimmed its holdings in shares of Cencora, Inc. (NYSE:COR) by 53.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,328 shares of the company’s stock after selling 10,566 shares during the quarter. Avanza Fonder AB’s holdings in Cencora were worth $3,151,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of COR. Vanguard Group Inc. grew its stake in Cencora by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock valued at $7,311,810,000 after purchasing an additional 916,506 shares in the last quarter. State Street Corp raised its position in shares of Cencora by 9.3% in the 3rd quarter. State Street Corp now owns 9,190,316 shares of the company’s stock valued at $2,872,249,000 after purchasing an additional 782,911 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Cencora by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock valued at $1,461,965,000 after purchasing an additional 821,098 shares in the last quarter. Boston Partners boosted its stake in shares of Cencora by 2.0% during the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after buying an additional 89,506 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Cencora by 3.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,971,121 shares of the company’s stock valued at $1,241,094,000 after buying an additional 115,278 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of research analyst reports. Barclays lifted their price target on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. Bank of America reduced their price objective on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Robert W. Baird set a $415.00 price objective on shares of Cencora in a report on Tuesday, January 13th. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. increased their price target on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Twelve research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $403.17.

Cencora Trading Up 2.0%

Cencora stock opened at $327.12 on Wednesday. Cencora, Inc. has a 52-week low of $265.59 and a 52-week high of $377.54. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The firm has a market capitalization of $63.63 billion, a price-to-earnings ratio of 39.32, a PEG ratio of 1.49 and a beta of 0.68. The firm has a 50-day moving average price of $354.13 and a two-hundred day moving average price of $340.68.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating the consensus estimate of $4.04 by $0.04. The company had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. Cencora’s revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the business earned $3.73 earnings per share. Sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s dividend payout ratio (DPR) is currently 28.85%.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at $23,669,713.98. The trade was a 7.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.38% of the stock is owned by insiders.

Cencora News Summary

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: The acquisition expands Cencora’s Retina Consultants of America platform and strengthens its footprint in the fast-growing eye care market, adding scale and potential cross-selling opportunities for pharma and services. Cencora to buy EyeSouth’s retina business for $1.1 billion
• Positive Sentiment: Analyst and trade coverage frames the deal as a clear add-on to RCA that builds scale in a specialty with high procedure volumes and recurring treatment needs, which could support revenue and margin improvement over time. COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal
• Neutral Sentiment: The transaction is widely reported across outlets (Reuters, Seeking Alpha, Fierce Healthcare), which helps transparency and may accelerate investor re-pricing; details on financing and expected contribution to guidance remain limited. Cencora to buy retina business of EyeSouth Partners for $1.1 billion
• Neutral Sentiment: COR is included in actively managed ETF baskets highlighted by MarketBeat, which can bring incremental demand from fund flows rather than direct company fundamentals. That placement may amplify moves in COR shares as funds trade. Active ETFs Surge Past Passive, and These Are in the Lead (COR)
• Negative Sentiment: Potential near-term negatives include transaction financing, integration costs and execution risk; Cencora already carries a relatively high debt-to-equity ratio, so investors should watch how the deal is funded and whether it materially affects leverage. Conshohocken’s Cencora Prepares for Leadership Change This Summer

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.